The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179682410

Prominent players in the respiratory drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).

Currently, North America dominates the pulmonary drug delivery devices market, and Asia represents the second-largest regional market. Moreover, the Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing geriatric population, growing adoption of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region.

Target Audience:

Pulmonary drug delivery devices and formulation manufacturers
Public and private physicians
Healthcare institutions (Medical data centers)
Research & clinical laboratories
Distributors and suppliers of pulmonary drug delivery devices
Health insurance companies
Market research and consulting firms